Silence Therapeutics plc (NASDAQ:SLN) Q4 2022 Earnings Call Transcript

Page 4 of 4

Operator: I will now hand the call back to Craig Tooman for closing remarks.

Craig Tooman: Thank you, everybody, for joining us on this call. I’m extremely proud of our 2022 performance and overall results. As I mentioned in the beginning of this call, 2023 is going to be very exciting for us from an execution and growth perspective. And we clearly highlighted some of the milestones, including the top line multiple dose SLN360 data from APOLLO by year-end, top line multiple dose data from SLN124 in thalassemia and the complete enrollment of Phase II in the SLN360 ASCVD trial. So a lot happening by year-end and we look forward to keeping you updated on our progress. Thank you and have a great day.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.

Follow Southland Holdings Inc.

Page 4 of 4